Evidence map›Paper›PMID 25137149›Full record

ArticleThe Journal of organic chemistry2014

Synthesis of a poly-hydroxypyrolidine-based inhibitor of Mycobacterium tuberculosis GlgE.

Sri Kumar Veleti, Jared J Lindenberger, Sandeep Thanna, Donald R Ronning, Steven J Sucheck

Open access · bronzeAbstract read
In one paragraph

Article in The Journal of organic chemistry, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed
1.9field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed, 29 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Direct Synthesis of Glycosyl Chlorides from Thioglycosides.The Journal of organic chemistry · 2024
    Article
  5. Article
  6. Activation of Thioglycosides with Copper(II) Bromide.Molecules (Basel, Switzerland) · 2022
    Article
  7. Synthesis of CFrontiers in chemistry · 2022
    Article
  8. Article
  9. Palladium(II)-assisted activation of thioglycosides.Organic & biomolecular chemistry · 2021
    Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Sri Kumar VeletiDepartment of Chemistry and Biochemistry, School of Green Chemistry and Engineering, The University of Toledo , 2801 West Bancroft Street, Toledo, Ohio 43606, United States.
Jared J Lindenberger
Sandeep Thanna
Donald R Ronning
Steven J Sucheck
University of Toledo · US

Funding

Understanding trehalose synthesis and utilization in mycobacteriaR01AI105084 · NIAID · UNIVERSITY OF TOLEDO · PI RONNING, DONALD R, SUCHECK, STEVEN · 2013 to 2022
$3.7M
NIAID NIH HHS AI105084NIAID NIH HHS R01 AI105084
6 · The paper itself

Abstract

Long treatment times, poor drug compliance, and natural selection during treatment of Mycobacterium tuberculosis (Mtb) have given rise to extensively drug-resistant tuberculosis (XDR-TB). As a result, there is a need to identify new antituberculosis drug targets. Mtb GlgE is a maltosyl transferase involved in α-glucan biosynthesis. Mutation of GlgE in Mtb increases the concentration of maltose-1-phosphate (M1P), one substrate for GlgE, causing rapid cell death. We have designed 2,5-dideoxy-3-O-α-d-glucopyranosyl-2,5-imino-d-mannitol (9) to act as an inhibitor of GlgE. Compound 9 was synthesized using a convergent synthesis by coupling thioglycosyl donor 14 and 5-azido-3-O-benzyl-5-deoxy-1,2-O-isopropylidene-β-d-fructopyranose (23) to form disaccharide 24. A reduction and intramolecular reductive amination transformed the intermediate disaccharide 24 to the desired pyrolidine 9. Compound 9 inhibited both Mtb GlgE and a variant of Streptomyces coelicolor (Sco) GlgEI with Ki = 237 ± 27 μM and Ki = 102 ± 7.52 μM, respectively. The results confirm that a Sco GlgE-V279S variant can be used as a model for Mtb GlgE. In conclusion, we designed a lead transition state inhibitor of GlgE, which will be instrumental in further elucidation of the enzymatic mechanism of Mtb GlgE.

Indexed as

Antitubercular AgentsBacterial ProteinsDisaccharidesDrug Resistance, BacterialEnzyme InhibitorsGlucansGlucosyltransferasesMolecular StructureMycobacterium tuberculosisSugar Phosphates2,5-dideoxy-3-O-alpha-D-glucopyranosyl-2,5-imino-D-mannitolAntitubercular AgentsBacterial ProteinsDisaccharidesEnzyme InhibitorsGlucansGlucosyltransferasesmaltose 1-phosphatemaltosyltransferaseSugar Phosphates

Identifiers

PMID25137149
PMCPMC4201354
OpenAlexW2324519019

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.